MarketPulse

biologic therapy

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Dupixent Wins FDA Nod for Young Children With Chronic Urticaria, Expanding Market Reach

FDA approves Dupixent for children ages 2-11 with uncontrolled chronic spontaneous urticaria, marking first biologic treatment for this pediatric population.
SNYREGNchronic spontaneous urticariaFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Argenx Se

argenx Expands VYVGART Leadership with Positive Phase 3 Data Across MG and CIDP

argenx presents Phase 3 data supporting VYVGART expansion across ocular MG, seronegative MG, and treatment-naïve CIDP, with 87.5% early benefit rates.
ARGXFDA approvalPhase 3 trials
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Argenx's Vyvgart Poised for Explosive Growth as Autoimmune Market Expands

Argenx's Vyvgart gains momentum with Japan approval and Fujifilm partnership, positioning the FcRn inhibitor for significant market expansion across multiple autoimmune indications through 2030.
ARGXFUJIYVYVGARTbiologic therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Skeletal Dysplasia Market Set to Surge 54% to $5.37B by 2032

Global skeletal dysplasia market projected to grow from $3.48B (2026) to $5.37B (2032) at 7.42% CAGR, driven by diagnostic advances and innovative therapies.
PFENVSRAREREGNBMRNrare diseasebiologic therapy
BenzingaBenzinga··Vandana Singh

Argenx Reports Phase 3 Success for VYVGART in Ocular Myasthenia Gravis

Argenx's VYVGART achieves Phase 3 success for ocular myasthenia gravis, meeting primary endpoint. Company plans FDA application to expand indication for the rare eye disorder treatment.
ARGXPhase 3 clinical trialFDA approval